An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)

Contact:

212-342-5162

NCT Number:

NCT03970447

Protocol:

AAAS2589

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II/III

The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people.

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older?
  • Do you have a newly diagnosed or recurrent Glioblastoma?
  • Are you willing and able to provide written informed consent and to comply with the study protocol as judged by the Investigator?

Specialty Area(s)

Brain and Spinal Tumors

Principal Investigator

Andrew B. Lassman, MD

Profile Headshot
  • Chief, Division of Neuro-Oncology
  • Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center
  • Associate Dean of Clinical Research Compliance, Vagelos College of Physicians & Surgeons, Columbia University
  • Scientific Director, Network Capacity Resource, Irving Institute for Clinical & Translational Research

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps
ColumbiaDoctors - Midtown
51 West 51st Street
New York, NY 10019
Open location in Google Maps